It is fast becoming a fact for life sciences industry leaders that there are few blue oceans left to explore. The therapeutic
areas still free from competition are extremely difficult to tackle as the failure from aducanumab demonstrates in
Alzheimer disease; an example where a top-notch innovator fails to crack the codes of one of the few remaining
areas with no treatment options. Flocking towards orphan drugs has been the latest solution for companies to keep
up with market expectations. Despite an increasing number of drugs being approved for rare diseases, the sales of
orphan medicines should barely represent 20% of the worldwide prescription sales leaving most of the market a sea
of red. This BASE life science whitepaper focuses on determining how simple technology tweaks can support the
creation of a competitive advantage.
Pharmaceutical companies are receiving an ever-increasing number of inquiries. A variety of factors, including increased product complexity and events…
